Search Patents
  • OXAZOLE OREXIN RECEPTOR ANTAGONISTS
    Publication number: 20160176858
    Abstract: The present invention is directed to oxazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the oxazole compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: August 4, 2014
    Publication date: June 23, 2016
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: NIGEL LIVERTON, DOUGLAS C. BESHORE, SCOTT D. KUDUK, YUNFU LUO, NA MENG, TINGTING YU
  • Antihypercholesterolemic compounds
    Patent number: 4916162
    Abstract: Novel 3-hydroxy-3-methylglutary-coenzyme A (HMG-CoA) reductase inhibitors which are useful as antihypercholesterolemic agents and are represented by the following general structural formulae (I) and (II): ##STR1## and pharmaceutically acceptable salts of the compounds (II) in which Z is hydrogen are disclosed.
    Type: Grant
    Filed: July 18, 1988
    Date of Patent: April 10, 1990
    Assignee: Merck & Co., Inc.
    Inventors: William F. Hoffman, Clarence S. Rooney, Ta Jyh Lee
  • MOISTURE PROTECTION FEATURES FOR A BOTTLE FOR STORING SOLID PHARMACEUTICAL PRODUCTS AND METHODS OF MAKING SAME
    Publication number: 20230172805
    Abstract: A bottle for storing solid pharmaceutical products includes a substantially cylindrical body having a sidewall, a top and a base defining an interior chamber, a first opening disposed on the top of the body, the first opening providing communication to the interior chamber and being eccentric with respect to the central longitudinal axis of the body, and a second opening disposed adjacent the first opening, the second opening being smaller than the first opening.
    Type: Application
    Filed: March 25, 2021
    Publication date: June 8, 2023
    Applicant: MERCK SHARP & DOHME LLC
    Inventors: Wail A. RASHEED, Cassie R. MEGNA, Ophelia L. WELLS, John B. CLINE
  • Hydrazono-malonitriles
    Patent number: 7544684
    Abstract: Hydrazono-malonitrile derivatives of the formula (I) in which R1, R2, R3, R3? and R4 have the meanings given in Claim 1 act as phosphodiesterase IV inhibitors and can be employed for the treatment of osteoporosis, tumors, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, myocardial diseases and AIDS.
    Type: Grant
    Filed: August 2, 2006
    Date of Patent: June 9, 2009
    Assignee: Merck Patent GmbH
    Inventors: Hans-Michael Eggenweiler, Michael Wolf, Norbert Beier, Pierre Schelling, Thomas Ehring
  • FUSED [7,5] BICYCLIC PYRAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF HERPESVIRUSES
    Publication number: 20240051963
    Abstract: The present invention relates to novel Fused [7,5] Bicyclic Pyrazole Derivatives of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, and R4 are as defined herein. The present invention also relates to compositions comprising at least one Fused [7,5] Bicyclic Pyrazole Derivative, and methods of using the Fused [7,5] Bicyclic Pyrazole Derivatives for treating or preventing a herpesvirus infection in a patient.
    Type: Application
    Filed: December 9, 2021
    Publication date: February 15, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Andrew J. Cooke, JR., Jeffrey W. Schubert, Jason W. Skudlarek
  • 17 .beta.-carboxanilides of 4-aza-5.alpha.-androstan-3-ones as 5.alpha.-reductase inhibitors
    Patent number: 5693810
    Abstract: Described are new 17.beta.-carboxanilides of 4-aza-5.alpha.-androstan-3-ones and related compounds of structural formula I: ##STR1## and the use of such compounds as 5.alpha.-reductase inhibitors for treatment of benign prostatic hyperplasia acne, seborrhea, female hirsutism, prostatitis, and prostatic carcinoma and other hyperandrogenetic related disorders.
    Type: Grant
    Filed: March 21, 1995
    Date of Patent: December 2, 1997
    Assignee: Merck & Co., Inc.
    Inventors: Gary H. Rasmusson, Raman K. Bakshi, Gool F. Patel
  • Process for functional expression of the para cation channel
    Patent number: 5593864
    Abstract: DNAs encoding voltage-activated cation channels have been cloned and characterized. The cDNA's have been expressed in recombinant host cells which produce active recombinant protein. The recombinant protein is also purified from the recombinant host cells.
    Type: Grant
    Filed: November 10, 1994
    Date of Patent: January 14, 1997
    Assignees: Merck & Co., Inc., The Research Foundation of State University of New York
    Inventors: Joseph P. Arena, Guoping Feng, Linda M. Hall, Ken Liu, Leonardus H. T. Van Der Ploeg, Peiyi Wang, Jeffrey W. Warmke
  • Optical compensator for LCD including stacked films of only one O-plate, one A-plate and two negative C-plate retarders
    Patent number: 6867834
    Abstract: An optical compensator for liquid crystal displays comprising at least one O plate retarder, at least one low tilt A plate retarder, and at least one negative C plate retarder is described. Also described are liquid crystal displays comprising such a compensator.
    Type: Grant
    Filed: September 13, 2000
    Date of Patent: March 15, 2005
    Assignee: Merck Patent GmbH
    Inventors: David Coates, Tara Cutler, Owain Llyr Parri, Mark Verrall, Peter Le Masurier, Stephan Derow
  • Indole diterpene alkaloid compounds
    Patent number: 5541208
    Abstract: The present invention relates to compounds of the formula: ##STR1## and the pharmaceutically acceptable salts thereof which are useful as potassium channel antagonists, particularly Maxi-K channel antagonists, and thus useful in treating Alzheimer's Disease and other cognitive disorders. This invention is also related to a method of making the compound of formula (I).
    Type: Grant
    Filed: January 24, 1994
    Date of Patent: July 30, 1996
    Assignee: Merck & Co., Inc.
    Inventors: Maria L. Garcia, Robert A. Giacobbe, Otto D. Hensens, Seok H. Lee, Owen B. McManus, Deborah L. Zink
  • Crystalline forms of MC4R agonist and process for synthesis
    Patent number: 8129413
    Abstract: The present invention relates to a process for producing N-{(1S)-1-[2-(1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5-chlorophenyl]ethyl}acetamide, and novel crystalline salts, hydrates, solvates, and polymorphic forms thereof.
    Type: Grant
    Filed: June 23, 2006
    Date of Patent: March 6, 2012
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Ralph Calabria, Yu Cheng, Russell R. Ferlita, Ashkan Kamali, Jerry A. Murry, David Mathre, Andrey V. Peresypkin, Karen Thompson, Jian Wang, Robert M. Wenslow
  • Gastrin releasing peptide antagonist
    Patent number: 5047502
    Abstract: Small cell lung carcinoma cells (SCLC) contain gastrin releasing peptide (GRP) receptors. The response of the cells to GRP is rapid growth. We have found a group of heptapeptides that act as GRP antagonists by blocking the binding of GRP to its receptor thereby inhibiting the growth of cells that are sensitive to the growth promoting acitivity of GRP.
    Type: Grant
    Filed: August 3, 1989
    Date of Patent: September 10, 1991
    Assignee: Merck and Co., Inc.
    Inventors: Allen I. Oliff, David C. Heimbrook, Mark W. Riemen, Victor M. Garsky
  • Liquid crystal mixture and liquid crystal display
    Patent number: 11053442
    Abstract: The invention relates to a liquid crystal mixture characterised in that it comprises one or more photoreactive mesogens of formula I wherein the parameters and groups occurring are defined as indicated in claim 1, to a process for the fabrication of liquid crystal displays using these liquid crystal mixtures and to a liquid crystal display obtainable by this process. The invention further relates to new compounds of formula I.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: July 6, 2021
    Assignee: MERCK PATENT GMBH
    Inventors: Kevin Adlem, Alex Davis, Joseph Sargent, Ian Charles Sage, Edward Plummer, Izumi Saito, Rocco Fortte, Helga Haas, Lars Lietzau
  • PROCESS FOR MAKING BETA 3 AGONISTS AND INTERMEDIATES
    Publication number: 20150087832
    Abstract: The present invention is directed to processes for preparing beta 3 agonists of Formula (I) and Formula (II) and their intermediates. The beta 3 agonists are useful in the treatment of certain disorders, including overactive bladder, urinary incontinence, and urinary urgency.
    Type: Application
    Filed: October 22, 2012
    Publication date: March 26, 2015
    Applicant: MERCK SHARP & DOHME, CORP.
    Inventors: John Y.L. Chung, Kevin Campos, Edward Cleator, Robert F. Dunn, Andrew Gibson, R. Scott Hoerrner, Stephen Keen, Dave Liebermann, Zhuqing Liu, Joseph Lynch, Kevine M. Maloney, Feng Xu, Nobuyoshi Yasuda, Naoki Yoshikawa, Yong-Li Zhong
  • Multilayered interference pigments
    Publication number: 20030039836
    Abstract: The invention relates to multilayered interference pigments which comprise a platelet-shaped substrate of silicon dioxide which is coated alternately with layers of light-transparent materials having refractive indices of n>1.8 and layers of light-transparent materials having refractive indices of n≦1.8, where the optical thickness of the platelet-shaped substrate and the optical thickness of the individual layers of light-transparent materials having refractive indices of n≦1.8 are the same.
    Type: Application
    Filed: August 2, 2002
    Publication date: February 27, 2003
    Applicant: Merck Patent GmbH
    Inventors: Gerhard Pfaff, Helge Kniess, Peter Reynders
  • Liquid-crystalline medium and liquid-crystal display
    Publication number: 20100276635
    Abstract: Disclosed are dielectrically positive liquid-crystalline media containing a dielectrically positive component, component A, containing one or more dielectrically positive compounds of formula I and optionally a second dielectrically positive component, component B, containing one or more dielectrically positive compounds having a dielectric anisotropy of greater than 3, and optionally a dielectrically neutral component, component C, and to liquid-crystal displays, especially active-matrix displays and in particular TN, OCB, IPS and FFS displays, containing these media.
    Type: Application
    Filed: April 28, 2010
    Publication date: November 4, 2010
    Applicant: Merck Patent GMBH
    Inventors: Michael Wittek, Brigitte Schuler, Lars Lietzau
  • Substituted imidazo[1,2-a]pyrazines, pyrazolo[1,5-c]pyrimidines, pyrazolo[1,5-a]pyridines, and purines for the treatment of schistosomiasis
    Patent number: 11046700
    Abstract: The present invention relates to compounds of formula (1a), formula (1b), formula (1c) or formula (1d): or, or a pharmaceutically acceptable salt thereof, which have activity as inhibitors of Schistosoma growth. The invention also relates to pharmaceutical compositions comprising such compounds, salts or solvates and to the use of such compounds as medicaments, in particular in the treatment or prevention of schistosomiasis, also known as bilharzia.
    Type: Grant
    Filed: January 15, 2018
    Date of Patent: June 29, 2021
    Assignee: Merck Patent GmbH
    Inventors: John Mark Francis Gardner, Andrew Simon Bell
  • HIV protease inhibitors useful for the treatment of AIDS
    Patent number: 5846978
    Abstract: Compounds such as ##STR1## or pharmaceutically acceptable salts thereof, are HIV protease inhibitors. These compounds are useful in the prevention or treatment of infection by HIV and in the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.
    Type: Grant
    Filed: May 2, 1997
    Date of Patent: December 8, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Craig A. Coburn, Mark E. Fraley, M. Katharine Holloway, Randall W. Hungate, Kristine Prendergast
  • Combination therapy using anti-EGFR antibodies and anti-hormonal agents
    Publication number: 20070202101
    Abstract: The invention relates to a combination therapy for the treatment of tumors and tumor metastases, preferably breast and prostate tumors, comprising administration of anti-EGFR (Her1) antibodies and anti-hormonal agents, optionally together with cytotoxic/chemotherapeutic agent. The method and the pharmaceutical compositions comprising said agents can result in a synergistic potentiation of the tumor cell proliferation inhibition effect of each individual therapeutic agent, yielding more effective treatment than found by administering an individual component alone.
    Type: Application
    Filed: April 26, 2007
    Publication date: August 30, 2007
    Applicant: Merck Patent GmbH
    Inventors: Oliver Rosen, Andreas Harstrick
  • Interlayer for electronic devices
    Patent number: 9583713
    Abstract: Embodiments in accordance with the present invention provide for the use of polycycloolefins in electronic devices and more specifically to the use of such polycycloolefins as interlayers applied to fluoropolymer layers used in the fabrication of electronic devices, the electronic devices that encompass such polycycloolefin interlayers and processes for preparing such polycycloolefin interlayers and electronic devices.
    Type: Grant
    Filed: September 1, 2011
    Date of Patent: February 28, 2017
    Assignees: Merck Patent GmbH, Promerus LLC
    Inventors: David Christoph Mueller, Pawel Miskiewicz, Toby Cull, Piotr Wierzchowiec, Andrew Bell, Edmund Elce, Larry F. Rhodes, Kazuyoshi Fujita, Hendra Ng, Pramod Kandanarachchi, Steven Smith
  • Thienothiophene derivatives
    Publication number: 20030021912
    Abstract: The invention relates to new thienothiophene derivatives, their use as semiconductors or charge transport materials, in optical, electrooptical or electronic devices like for example organic field effect transistors (FET or OFET) for thin film transistor liquid crystal displays and integrated circuit devices such as RFID tags, electroluminescent devices in flat panel displays, and in photovoltaic and sensor devices, and to a field effect transistor, light emitting device or ID tag comprising the thienothiophene derivatives.
    Type: Application
    Filed: July 9, 2002
    Publication date: January 30, 2003
    Applicant: Merck Patent GmbH
    Inventors: Louise Farrand, Marcus Thompson, Mark Giles, Martin Heeney, Steven Tierney, Maxim Shkunov, David Sparrowe, Iain McCulloch
Narrow Results

Filter by US Classification